| Literature DB >> 32316373 |
Sophie Kittler1, Ruth Mengden2, Imke H E Korf3, Anna Bierbrodt4, Johannes Wittmann3, Madeleine Plötz1, Arne Jung5, Tatiana Lehnherr6, Christine Rohde3, Hansjörg Lehnherr6, Günter Klein1, Corinna Kehrenberg7.
Abstract
Among intestinal coliform microbes in the broiler gut, there are potentially pathogenic Escherichia (E.) coli that can cause avian colibacillosis. The treatment with antibiotics favors the selection of multidrug-resistant bacteria and an alternative to this treatment is urgently required. A chicken model of intestinal colonization with an apathogenic model strain of E. coli was used to test if oral phage application can prevent or reduce the gut colonization of extraintestinal pathogenic E. coli variants in two individual experiments. The E. coli strain E28 was used as a model strain, which could be differentiated from other E. coli strains colonizing the broiler gut, and was susceptible to all cocktail phages applied. In the first trial, a mixture of six phages was continuously applied via drinking water. No reduction of the model E. coli strain E28 occurred, but phage replication could be demonstrated. In the second trial, the applied mixture was limited to the four phages, which showed highest efficacy in vitro. E. coli colonization was reduced in this trial, but again, no reduction of the E. coli strain E28 was observed. The results of the trials presented here can improve the understanding of the effect of phages on single strains in the multi-strain microbiota of the chicken gut.Entities:
Keywords: E. coli; ExPEC; bacteriophages; chicken microflora; colibacillosis; microbiota; multidrug resistance; phages
Year: 2020 PMID: 32316373 PMCID: PMC7238078 DOI: 10.3390/pathogens9040293
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Figure 1Mean difference of bacterial concentrations in the experimental group compared with the control. Drinking water of the experimental group was supplemented with a phage cocktail in both experiments, containing six (a) or four (b) phages, respectively. Counts in the control group resemble the baseline. Patterned bars represent mean differences in fecal concentrations of the model strain E. coli E28, while grey bars represent mean differences of fecal E. coli. Error bars show confidence intervals of the difference between the means of the control and experimental groups. Differences are significant if confidence intervals include the baseline. (a) Six-phage trial (cocktail containing the phages TriM, AB27, EW2, TB49, KRA2, and G28), (b) four-phage trial (cocktail containing the phages AB27, EW2, TB49, and G28). CFU Colony forming units.
Mean bacterial counts in feces (log10 colony forming units (CFU)/g feces ± SEM). dph = days post hatch (Supplementary Materials).
| Six-Phage Trial | 6 dph | 7 dph | 9 dph | 14 dph | 21 dph | 28 dph | 35 dph | |
|---|---|---|---|---|---|---|---|---|
|
| control | 8.0 ± 0.1 | 6.2 ± 0.5 | 6.2 ± 0.3 | 6.6 ± 0.3 | 6.7 ± 0.3 | 6.3 ± 0.3 | 6.5 ± 0.4 |
| phage group | 8.5 ± 0.1 | 7.1 ± 0.3 | 7.6 ± 0.2 | 6.7 ± 0.5 | 6.8 ± 0.2 | 6.9 ± 0.2 | 6.8 ± 0.2 | |
| Model strain E28 | control | 8.4 ± 0.1 | 6.1 ± 0.3 | 4.2 ± 0.4 | 4.0 ± 0.4 | 3.9 ± 0.4 | 3.7 ± 0.3 | 3.7 ± 0.4 |
| phage group | 7.7 ± 0.5 | 6.6 ± 0.3 | 6.7 ± 0.2 | 5.6 ± 0.3 | 5.2 ± 0.3 | 5.6 ± 0.4 | 5.8 ± 0.3 | |
| Four-phage trial | 6 dph | 8 dph | - | 15 dph | 22 dph | 29 dph | 36 dph | |
|
| control | 6.5 ± 0.3 | 6.5 ± 0.4 | - | 6.3 ± 0.3 | 6.5 ± 0.3 | 7.0 ± 0.2 | 5.9 ± 0.3 |
| phage group | 1.7 ± 0.3 | 3.6 ± 0.5 | - | 6.0 ± 0.2 | 5.8 ± 0.2 | 6.0 ± 0.2 | 6.0 ± 0.3 | |
| Model strain E28 | control | 0.0 ± 0.0 | 0.4 ± 0.2 | - | 2.7 ± 0.4 | 4.1 ± 0.4 | 5.7 ± 0.4 | 3.8 ± 0.4 |
| phage group | 0.0 ± 0.0 | 2.6 ± 0.7 | - | 4.9 ± 0.3 | 5.2 ± 0.2 | 5.1 ± 0.3 | 5.3 ± 0.4 |
Mean phage counts in feces compared with expected excretion without phage replication and intake dose in the phage group.
| Six-Phage Trial | 6 dph | 7 dph | 9 dph | 14 dph | 21 dph | 28 dph | 35 dph |
|---|---|---|---|---|---|---|---|
| Phage counts (log10 PFU/g feces) | 7.3 | 6.1 | 4.8 | n.d. c | 4.1 | n.d. c | 5.1 |
|
|
|
|
| ||||
| Intake dose (log10 PFU/mL water) b | n.d. c | 4.2 | n.d. c | 4.8 | n.d. c | 4.2 | n.d. c |
| Four-phage trial | 6 dph | 8 dph | - | 15 dph | 22 dph | 29 dph | 36 dph |
| Phage counts (log10 PFU/g feces) | n.d. c | 3.5 | n.d. c | 6.4 | 6.9 | 6.3 | 6.3 |
|
|
|
|
| ||||
| Intake dose (log10 PFU/mL water) b | n.d. c | n.d. c | n.d. c | 5.6 | 7.3 | 7.0 | n.d. c |
a Estimated by the water loss of the drinkers per bird, the phage dose in the drinkers and daily intake of feed (g), given by the performance objectives for Ross 308 broilers. b The intake dose of phages per mL water was calculated as a mean of measured phages concentrations in drinking water at the indicated days. c No samples or data were obtained for the indicated days. d In the four-phage trial 15 days post hatch, water intake volume was not available and expected excretion could thus not be calculated. dph = days post hatch; PFU = plaque forming units.
Proportion of E28 re-isolates showing reduced phage susceptibility (%).
| Six-Phage Trial a | Cocktail | EW2 | KRA2 | TB49 | AB27 | TriM | G28 |
|---|---|---|---|---|---|---|---|
| Phage group | 2 | 12 | 10 | 0 | 4 | 2 | 0 |
| Control | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Four-phage trial b | Cocktail | EW2 | - | TB49 | AB27 | - | G28 |
| Phage group | 0 | 20 | - | 10 | 7 | - | 0 |
| Control | 0 | 0 | - | 4 | 0 | - | 0 |
a Reduced efficiency of plating (EOP, serial dilution) by a minimum of 2 log10 compared with the original E28. b Reduced plaque formation in overlays by a minimum of 2 log10 compared with the original E28.
Growth, phage susceptibility pattern, and metabolic characteristics of selected re-isolates.
| Characteristics | ||||
|---|---|---|---|---|
| Isolate | Phage Susceptibility Pattern b | Reduced Utilization Carbon Sources (%) c | Increased Utilization Carbon Sources (%) c | Growth Curve in Broth |
| Wildtype E28 | - | - | - | >1; <1.2 |
| Re-isolates six-phage trial | ||||
| 134 a | - | - | - | >1; <1.2 |
| 154 | - | - | - | >1; <1.2 |
| 183 | (TB49) | - | 1 | >1; <1.2 |
| 116 | (TB49) | 38 | 7 | <1 |
| 179 | EW2, (TB49), (KRA2) | - | 2 | >1; <1.2 |
| 185 | TriM, AB27, EW2, KRA2 | - | 1 | >1; <1.2 |
| 210 | TriM, AB27, EW2, KRA2 | - | 2 | >1; <1.2 |
| 156 | TriM, AB27, EW2, TB49, KRA2 | 8 | 22 | <1 |
| Re-isolates four-phage trail | ||||
| 22 a | - | - | 1 | >1; <1.2 |
| 16 | - | - | 1 | >1; <1.2 |
| 106 | (TB49) | - | 1 | >1; <1.2 |
| 120 | (TB49) | - | 1 | >1; <1.2 |
| 118 | TB49 | - | - | >1; <1.2 |
| 178 | AB27, EW2 | - | 1 | >1; <1.2 |
| 198 | AB27, EW2 | 1 | 1 | >1; <1.2 |
| 196 | AB27, (EW2), (TB49) | 2 | 1 | <1 |
| Non-E28 six-phage trial | ||||
| 617 a | TriM, AB27, EW2, TB49, KRA2, (G28) | - | 24 | >1; <1.2 |
| 630 a | TriM, AB27, EW2, TB49, KRA2, (G28) | 1 | 17 | >1.2 |
| 640 a | TriM, AB27, EW2, TB49, KRA2, (G28) | 2 | 13 | >1.2 |
| 650 a | TriM, (AB27), EW2, TB49, KRA2, G28 | 1 | 19 | >1.2 |
| Non-E28 four-phage trial | ||||
| 253 | AB27, EW2, TB49, G28 | - | 27 | >1.2 |
| 283 | AB27, (EW2), TB49, G28 | - | 26 | >1.2 |
| 311 | AB27, (EW2), TB49, G28 | - | 26 | >1; <1.2 |
a Isolates from the control group samples. b Phage acronyms in brackets indicate a reduction of susceptibility by a minimum of two orders of magnitude compared with the original E28, acronyms without breaks indicate total resistance (no plaques). Re-isolates of the six-phage trial were tested by efficiency of plating, and re-isolates of the four-phage trial were tested with suspensions containing log10 4 PFU/mL using the overlay technique, as described in Section 4. c Carbon source utilisation by the E28 re-isolates from supplemented tryptone bile X glucuronide (TBX) plates and by the non-E28 from TBX plates was tested using Biolog Phenotype Microarray GN2. d Growth curves were determined using a TECAN reader.